Skip to main content
. 2022 Aug 26;13:935444. doi: 10.3389/fmicb.2022.935444

Figure 1.

Figure 1

Enhanced immunogenicity in female SWR/J mice after treatment with drug and therapeutic ID93 vaccines. (A) Therapeutic study timeline; (B) Percent frequency of CD4 + CD44+ ID93-specific single-cytokine-producing cells; asterisks indicate significance where ***p < 0.001, ****p < 0.0001 using one-way ANOVA with Bonferroni’s multiple comparison correction; (C) ID93-specific CD4 + CD44+ polyfunctional Th1 cytokine-producing cells; (D) Mycobacterium tuberculosis lysate-specific CD4 + CD44+ polyfunctional Th1 cytokine-producing cells. Dots represent individual mice, with bars as the mean, and whiskers indicating SD. Asterisks indicate statistical significance, where **p < 0.01, ***p < 0.001, and ****p < 0.0001 using one-way ANOVA with Bonferroni’s multiple comparison correction.